Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biomunex Pharmaceuticals

Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting
From Biomunex Pharmaceuticals
Via Business Wire
Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology
From Biomunex Pharmaceuticals
Via Business Wire
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
From Biomunex Pharmaceuticals
Via Business Wire
Biomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting
From Biomunex Pharmaceuticals
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.